Combined Therapy of Catheter Ablation and Left Atrial Appendage Closure for Patients with Atrial Fibrillation: A Case-Control Study
Table 2
Baseline characteristics of the study population after propensity score matching.
Combined (n = 76)
CA-only (n = 76)
LAAC-only (n = 76)
†
Female
37 (48.7)
40 (52.6)
0.626
38 (50.0)
0.871
Age (years)
69.9 ± 7.9
69.5 ± 7.8
0.703
71.36 ± 8.9
0.300
BMI (kg/m2)
24.6 ± 3.2
24.9 ± 3.7
0.543
24.3 ± 3.3
0.644
Paroxysmal AF
37 (48.7)
38 (50.0)
0.871
27 (35.5)
0.100
Persistent AF
39 (51.3)
38 (50.0)
0.871
49 (64.5)
0.100
Coronary artery disease
16 (21.1)
15 (19.7)
0.840
18 (23.7)
0.426
Hypertension
56 (73.7)
54 (71.1)
0.717
57 (75.0)
0.853
Heart failure
23 (30.3)
21 (27.6)
0.721
19 (25.0)
0.468
Diabetes mellitus
14 (18.4)
15 (19.7)
0.836
15 (19.7)
0.836
Previous stroke/TIA/TE
23 (30.3)
15 (19.7)
0.134
20 (26.3)
0.589
Left atrial diameter (mm)
42.7 ± 5.7
41.7 ± 4.9
0.226
44.1 ± 5.9
0.163
LVEF (%)
63.9 ± 6.3
64.2 ± 5.4
0.746
62.7 ± 6.9
0.273
CHA2DS2-VASc score
3.6 ± 1.3
3.4 ± 1.4
0.484
3.7 ± 1.4
0.719
HAS-BLED score
3.3 ± 1.1
2.6 ± 0.9
<0.001
3.4 ± 1.1
0.413
Comparison between the combined group and the CA-only group. †Comparison between the combined group and the LAAC-only group. Values are mean ± SD or n (%) as appropriate. AF, atrial fibrillation; BMI, body mass index; CA, catheter ablation; LAA, left atrial appendage; LAAC, left atrial appendage closure; LVEF, left ventricular ejection fraction; TIA, transient ischemic attacks; TE, thromboembolism.
